Abstract
Cell-free DNA (cfDNA) screening has high detection for the common fetal autosomal aneuploidies, but is not diagnostic. The positive predictive value should be utilized in counseling after a positive cell-free DNA screen, and diagnostic testing should be offered for confirmation. cfDNA screening does not report a result in ~3% of cases; nonreportable results indicate an increased risk for aneuploidy and some adverse perinatal outcomes. False-positive cfDNA screening occurs due to confined placental mosaicism, maternal copy number variants, mosaicism, and cancer. Pretest education and counseling should be provided with emphasis on the potential benefits, risks, and limitations before cfDNA screening.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Obstetrics and Gynecology
Reference71 articles.
1. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study;Palomaki;Genet Med,2011
2. DNA sequencing versus standard prenatal aneuploidy screening;Bianchi;N Engl J Med,2014
3. Cell-free DNA analysis for noninvasive examination of trisomy;Norton;N Engl J Med,2015
4. Chromosomal microarray versus karyotyping for prenatal diagnosis;Wapner;N Engl J Med,2012
5. Non-invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18;Norton;Am J Obstet Gynecol,2012